Literature DB >> 32620576

Nuisance bleeding complications in patients with cerebral aneurysm treated with Pipeline embolization device.

Elliot Pressman1, Carlos A De la Garza2, Felix Chin3, Jacob Fishbein1, Muhammad Waqas3, Adnan Siddiqui3, Kenneth Snyder3, Jason M Davies3, Elad Levy3, Peter Kan4, Zeguang Ren1,5, Maxim Mokin6,5.   

Abstract

BACKGROUND: Patients with cerebral aneurysms treated with the Pipeline embolization device (PED) are maintained on dual antiplatelet therapy (DAPT) to prevent thromboembolic complications. Rates of minor, "nuisance" bleeding in these patients remain unknown. We sought to evaluate the frequency and factors associated with this bleeding and its effect on DAPT compliance.
METHODS: We performed a multicenter retrospective cohort study on consecutive cases of intracranial aneurysms treated with PED. Patient characteristics, aneurysm characteristics, and bleeding complications were analyzed. Severity of bleeding was defined according to a previously published classification defining nuisance bleeding as easy bruising, bleeding from small cuts, petechia, and ecchymosis.
RESULTS: 245 PED aneurysm procedures on 243 patients were retrospectively collected from three academic centers over a 4.25-year period. Sixty-seven patients (27%) had nuisance bleeds. Patients with a higher risk of nuisance bleeding were older (59.1±3.4 vs . 54.7±2.2, P=0.032). Patients with nuisance bleeds were more likely to have their DAPT regimen changed or dose lowered (29% vs 8.3%, P<0.001), were on DAPT for less time (10.0 months±2.60 vs. 14.6 months±1.95, P=0.005) and were more likely to have aneurysm occlusion at 6 months (P<0.001). Stepwise logistic regression found age predictive of a nuisance bleed (OR=1.033)
CONCLUSIONS: Nuisance bleeding was a common complaint of PED-treated aneurysm patients maintained on DAPT. Increasing age and aneurysmal occlusion at 6 months were the only factors predictive of nuisance bleeds. Clinicians were more likely to adjust antiplatelet regimens or stop DAPT early given a nuisance bleed. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  aneurysm; flow diverter; hemorrhage; platelets; stent

Mesh:

Year:  2020        PMID: 32620576     DOI: 10.1136/neurintsurg-2020-016245

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  4 in total

1.  Clinical Usage of Different Doses of Cis-Atracurium in Intracranial Aneurysm Surgery and Its Effect on Motor-Evoked Potentials.

Authors:  Zhongyuan Qiao; Rong Fan
Journal:  Comput Math Methods Med       Date:  2022-06-28       Impact factor: 2.809

2.  Flow diverter stents in the treatment of recanalized intracranial aneurysms.

Authors:  Erol Akgul; Hasan Bilen Onan; Irem Islek; Mehmet Tonge; Yavuz Durmus; Mehmet Barburoglu; Aynur Azizova; Cengiz Erol; Bahattin Hakyemez; Serra Sencer; Kubilay Aydin; Anil Arat
Journal:  Interv Neuroradiol       Date:  2021-01-28       Impact factor: 1.764

Review 3.  P2Y12 inhibitors for the neurointerventionalist.

Authors:  Robin J Borchert; Davide Simonato; Charlotte R Hickman; Maurizio Fuschi; Lucie Thibault; Hans Henkes; David Fiorella; Benjamin Yq Tan; Leonard Ll Yeo; Hegoda L D Makalanda; Ken Wong; Pervinder Bhogal
Journal:  Interv Neuroradiol       Date:  2021-05-04       Impact factor: 1.610

4.  Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment.

Authors:  Pervinder Bhogal; Andrey Petrov; Ganbaatar Rentsenkhu; Baatarjan Nota; Erdenebat Ganzorig; Boldbat Regzengombo; Sara Jagusch; Elina Henkes; Hans Henkes
Journal:  Interv Neuroradiol       Date:  2021-07-07       Impact factor: 1.764

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.